| Literature DB >> 27297135 |
Yoshihito Kano1, Jonathan D Cook2, Jeffrey E Lee2, Michael Ohh3.
Abstract
Mutations in RAS and various components of the Ras signaling pathways are among the most common causative genetic alterations in human cancers, accounting up to 25% of lung cancers and over 90% of pancreatic cancers. Ras is a small GTPase that functions as a 'molecular switch' in a number of signaling pathways that regulate vital eukaryotic cellular functions. Despite our comprehensive understanding of the molecular mechanisms governing the activity of Ras, the clinical outcome of various pharmacologic anti-cancer strategies designed to directly inactivate Ras have been less than satisfactory. In this review, the more recently uncovered mode of regulation of Ras involving non-receptor tyrosine kinase and phosphatase, which have long been suspected of contributing to the oncogenic potential of Ras, will be discussed in the context of both function and structure.Entities:
Keywords: GTPase cycle; Ras; Shp2; Src; Y32
Mesh:
Substances:
Year: 2016 PMID: 27297135 DOI: 10.1016/j.semcdb.2016.06.006
Source DB: PubMed Journal: Semin Cell Dev Biol ISSN: 1084-9521 Impact factor: 7.727